There are currently 446 clinical trials in Kansas City, Kansas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Kansas Medical Center, University of Kansas Cancer Center, Kansas University Medical Center and Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease
NCT03158896
Recruiting
This study evaluates the safety and effectiveness of two different doses of umbilical cord derived, ex-vivo cultured and expanded Wharton's jelly mesenchymal stem cells (MSCTC-0010) in the treatment of acute Graft versus Host Disease (aGVHD). The first 5 participants enrolled in the study will receive a lower dose of MSCTC-0010. If none of the first 5 participants have treatment-related serious adverse events (TRSAEs) for 42 days, then the next 5 participants will receive a slightly higher dose... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/22/2024
Locations: Kansas University Cancer Center, Kansas City, Kansas
Conditions: Acute Graft Versus Host Disease
Register for Updates
Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC
NCT05332925
Recruiting
To test whether it is feasible to perform the 3D-EX functional predictive response bioassay in the context of patients with advanced/metastatic NSCLC receiving immune checkpoint inhibitors in the standard of care clinical setting.
Gender:
ALL
Ages:
Between 18 years and 110 years
Trial Updated:
02/21/2024
Locations: The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas
Conditions: Lung Cancer, NSCLC, NSCLC Stage IV
Register for Updates
Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma
NCT06178588
Recruiting
This phase II trial tests how well sacituzumab govitecan works in treating patients with cholangiocarcinoma that has spread to nearby tissue or lymph nodes (locally advanced), that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Sacituzumab govitecan is a monoclonal antibody, called hRS7, linked to a toxic agent, called SN-38. HRS7 is a form of targeted therapy because it attaches to s... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2024
Locations: University of Kansas Cancer Center, Kansas City, Kansas
Conditions: Locally Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma, Recurrent Cholangiocarcinoma, Stage III Hilar Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hilar Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
Register for Updates
Enhancing PAP Adherence Among Spanish-speaking Hispanic Adults With OSA
NCT05618444
Recruiting
This study seeks to enhance long-term positive airway pressure (PAP) adherence among Spanish-speaking Hispanics, a group with known PAP outcomes disparities. This study will assess the feasibility of a linguistically and culturally adapted tele-management intervention (Automated Management, AM) for Spanish-speaking Hispanic adults with OSA.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/07/2024
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Obstructive Sleep Apnea
Register for Updates
The Acute Burn ResUscitation Multicenter Prospective Trial
NCT04356859
Recruiting
This is a prospective randomized multi-center study which will compare acute fluid resuscitation using a colloid strategy (LR + 5% Albumin) to a crystalloid strategy (LR alone), in adults with an acute burn involving at least 25% of their total body surface area.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2024
Locations: University of Kansas Health System, Kansas City, Kansas
Conditions: Burn Injury
Register for Updates
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728
Recruiting
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: Arizona Digestive Health - Sun City, Kansas City, Kansas +1 locations
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates
Family-Implemented Treatment on the Behavioral Inflexibility of Children With Autism
NCT05125003
Recruiting
The overall goal of this project is to determine whether a new form of family-based treatment for repetitive and inflexible behaviors, delivered using videoconferencing technology, can counter any negative effects of those behaviors, but also improve positive outcomes for young children with ASD.
Gender:
ALL
Ages:
Between 3 years and 9 years
Trial Updated:
01/19/2024
Locations: Juniper Gardens Children's Project, Kansas City, Kansas
Conditions: Autism Spectrum Disorder, Repetitive Compulsive Behavior
Register for Updates
Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC)
NCT04636775
Recruiting
This phase IV study is hoping to determine if examining the microbiome in non-small cell lung cancer, immunotherapy naive participants can predict the effectiveness of immunotherapy treatment as well as determine ahead of time adverse events and their severity. In addition, the investigator will look into microbiome changing modifiers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/08/2023
Locations: The University of Kansas Medical Center, Kansas City, Kansas +1 locations
Conditions: NSCLC Stage IV, NSCLC, Recurrent
Register for Updates
Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer
NCT04992780
Recruiting
The hypothesis for this study is that hypofractionated IMRT to 62.5 Gy in 25 fractions (2.5 Gy/fraction) with concurrent carboplatin and paclitaxel, followed by maintenance durvalumab will improve locoregional control at 18 months by 10% compared to standard-fractionated chemo-IMRT/durvalumab. A modest improvement in locoregional control (LRC) was selected as a target which could merit further study of this hypofractionated IMRT regimen in a Phase III trial
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2023
Locations: The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas
Conditions: Non Small Cell Lung Cancer Stage
Register for Updates
Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy
NCT04467801
Recruiting
For metastatic/advanced NSCLC patients who do not have targetable mutations, either immunotherapy targeting the programmed death-1 and its ligand (PD-1/L1) pathway alone or in combination with platinum doublet chemotherapy is now a standard of care. However, still about half of the patients do not benefit due to treatment resistance. It is therefore critically important to find novel therapies and combinations to benefit patients who have failed or are intolerant to 1st line immunotherapy. This... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/02/2023
Locations: The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas
Conditions: NSCLC Stage IV, NSCLC Stage IIIB
Register for Updates
Treatment of Complex Pilon Fractures
NCT06089525
Recruiting
This project intends to compare patient outcomes between patients undergoing ORIF compared to PA, or ankle fusion, following an acute pilon fracture. Limited literature comparing ORIF and ankle fusion as a primary procedure exists. Particularly, no present literature exists examining the novel arthrodesis surgical technique utilized in this study in conjunction with Opal sensor gait analysis data. This study will serve as a pilot study and assess patient gait, degree of pain, functional outcome... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/12/2023
Locations: The University of Kansas Medical Center, Kansas City, Kansas
Conditions: Pilon Fracture
Register for Updates
Efficacy of Point Of Service Testing in MBC
NCT03983577
Recruiting
This study will assess the efficacy of an innovative point of service cancer genetics counseling delivery model for metastatic breast cancer (MBC) patients whom have received a referral for hereditary cancer genetic counseling and testing.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/21/2023
Locations: The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas
Conditions: Metastatic Cancer, Breast Cancer
Register for Updates